دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Retained Metabolic Flexibility of the Failing Human Heart.
Watson, William D. BSc (Hons), DPhil, MBBChir, MRCP *,,; Green, Peregrine G. MA, DPhil, BMBCh, MRCP *,,; Lewis, Andrew J.M. DPhil; Arvidsson, Per MD, PhD; De Maria, Giovanni Luigi MD, PhD; Arheden, Hakan MD, PhD; Heiberg, Einar PhD; Clarke, William T. DPhil; Rodgers, Christopher T. DPhil; Valkovic, Ladislav PhD; Neubauer, Stefan MD; Herring, Neil DPhil *,; Rider, Oliver J. BA, BMBCh, DPhil *,
doi : 10.1161/CIRCULATIONAHA.122.062166
Volume 148(2) pgs. 109-195,e3-e3 July 11, 2023
The failing heart is traditionally described as metabolically inflexible and oxygen starved, causing energetic deficit and contractile dysfunction.
Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.
Greene, Stephen J. MD; Velazquez, Eric J. MD; Anstrom, Kevin J. PhD; Clare, Robert M. MS; DeWald, Tracy A. PharmD, MHS; Psotka, Mitchell A. MD; Ambrosy, Andrew P. MD; Stevens, Gerin R. MD, PhD; Rommel, John J. MD; Alexy, Tamas MD, PhD; Ketema, Fassil MSc; Kim, Dong-Yun PhD; Desvigne-Nickens, Patrice MD; Pitt, Bertram MD; Eisenstein, Eric L. DBA; Mentz, Robert J. MD; on behalf of the TRANSFORM-HF Investigators
doi : 10.1161/CIRCULATIONAHA.123.064842
Loop diuretics are a primary therapy for the symptomatic treatment of heart failure (HF), but whether torsemide improves patient symptoms and quality of life better than furosemide remains unknown.
Association of HIV Infection and Incident Abdominal Aortic Aneurysm Among 143 001 Veterans.
Filipkowski, Alexandra M. BS; Kundu, Suman DSc, MSc; Eden, Svetlana K. PhD; Alcorn, Charles W. MA; Justice, Amy C. MD, PhD; So-Armah, Kaku A. PhD; Tindle, Hilary A. MD, MPH; Wells, Quinn S. MD, PharmD, MSCI, MSc; Beckman, Joshua A. MD, MSc; Freiberg, Matthew S. MD, MSc; Aday, Aaron W. MD, MSc
doi : 10.1161/CIRCULATIONAHA.122.063040
People with HIV (PWH) have an increased risk of cardiovascular disease. Previous cross-sectional data suggest there is a higher prevalence of abdominal aortic aneurysm (AAA) in PWH than in those without HIV.
Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.
Johns, Douglas G. PhD *,; Campeau, Louis-Charles PhD *,; Banka, Puja MD; Bautmans, An DVM; Bueters, Tjerk PhD; Bianchi, Elisabetta MS; Branca, Danila MS; Bulger, Paul G. PhD; Crevecoeur, Inne PhD; Ding, Fa-Xiang MS; Garbaccio, Robert M. PhD; Guetschow, Erik D. PhD; Guo, Yan MS; Ha, Sookhee N. PhD; Johnston, Jennifer M. PhD; Josien, Hubert PhD; Kauh, Eunkyung A. MD; Koeplinger, Kenneth A. MS; Kuethe, Jeffrey T. PhD; Lai, Eseng MD; Lanning, Christine L. PhD; Lee, Anita Y.H. MS; Li, Li PhD; Nair, Anilkumar G. PhD; O'Neill, Edward A. PhD; Stoch, S. Aubrey MD; Thaisrivongs, David A. PhD; Tucker, Thomas J. BS; Vachal, Petr PhD; van Dyck, Kristien PhD; Vanhoutte, Frederic P. MD; Volckaert, Bram MD; Wolford, Dennis G. MS; Xu, Andy PharmD; Zhao, Tian PhD; Zhou, Dan PhD; Zhou, Susan PhD; Zhu, Xiaohong MS; Zokian, Hratch J. MS; Walji, Abbas M. PhD *,; Wood, Harold B. PhD *,
doi : 10.1161/CIRCULATIONAHA.122.063372
Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9)-low density lipoprotein receptor interaction with injectable monoclonal antibodies or small interfering RNA lowers plasma low density lipoprotein-cholesterol, but despite nearly 2 decades of effort, an oral inhibitor of PCSK9 is not available.
New Chapter in the PCSK9 Book: Oral Inhibition of PCSK9 Binding to the LDL Receptor With a Macrocyclic Peptide.
Landmesser, Ulf MD; Makhmudova, Umidakhon MD
Myocardial Neprilysin Is Increased in Hypertrophic Cardiomyopathy.
Armstrong, David W.J. MD, PhD; Riley, Lance A. PhD; Su, Yan Ru MD; Shah, Ashish S. MD; Absi, Tarek MD; Gupta, Deepak K. MD, MSCI; Wells, Quinn S. MD, PharmD, MSCI; Brinkley, D. Marshall MD; Stevenson, Lynne W. MD; Merryman, W. David PhD
Letter by Teng et al Regarding Article, "Direct Reprogramming Improves Cardiac Function and Reverses Fibrosis in Chronic Myocardial Infarction".
Teng, Zhenqing MS; Ma, Xiang PhD; Ma, Yitong PhD
Response by Sadahiro et al to Letter Regarding Article, "Direct Reprogramming Improves Cardiac Function and Reverses Fibrosis in Chronic Myocardial Infarction".
Sadahiro, Taketaro MD, PhD *,; Tani, Hidenori MD *,; Ieda, Masaki MD, PhD
Treatment Strategies for Cardiomyopathy in Children: A Scientific Statement From the American Heart Association.
Bogle, Carmel MD; Colan, Steven D. MD; Miyamoto, Shelley D. MD, FAHA; Choudhry, Swati MD; Baez-Hernandez, Nathanya MD; Brickler, Molly M. MSN, APNP; Feingold, Brian MD, MS, FAHA; Lal, Ashwin K. MD, FAHA; Lee, Teresa M. MD; Canter, Charles E. MD, FAHA, Vice Chair; Lipshultz, Steven E. MD, FAHA, Chair; on behalf of the American Heart Association Young Hearts Pediatric Heart Failure and Transplantation Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young (Young Hearts)
doi : 10.1161/CIR.0000000000001151
AB This scientific statement from the American Heart Association focuses on treatment strategies and modalities for cardiomyopathy (heart muscle disease) in children and serves as a companion scientific statement for the recent statement on the classification and diagnosis of cardiomyopathy in children.
Correction to: Treatment Strategies for Cardiomyopathy in Children: A Scientific Statement From the American Heart Association.
